Compass Pathways Names U.S. Grant Recipients for COMP360 Training
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
PTSD
Advertisement
EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
Definium Therapeutics Gains FDA Breakthrough Therapy Designation for DT120 in MDD
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
Alzamend Neuro Shares Lithium Imaging Data at Neuroscience 2026
Atlanta, Georgia, August 20, 2026 Alzamend Neuro, Inc. has announced that data from its Phase 1/2A clinical trial of...
Silo Pharma Advances Canadian Patent for PTSD Therapy
SARASOTA, Fla., August 18, 2026 Silo Pharma, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a...
Advertisements
Silo Pharma Gains European Patent for SPC-15 PTSD Therapy
SARASOTA, Fla., August 10, 2026 Silo Pharma, Inc. announced that the European Patent Office (EPO) has granted a patent...
MAPS Responds to FDA Progress on MDMA-Assisted PTSD Therapy
Denver, Colorado, USA — August 10, 2026 Multidisciplinary Association for Psychedelic Studies (MAPS) responded to reports that Resilient Pharmaceuticals,...
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Silo Pharma Advances SPC-15 PTSD Program Toward FDA Meeting
SARASOTA, Fla., June 29, 2026 Silo Pharma announced that it has initiated a drug-device robustness study for SPC-15, its...
Advertisement
